The word "focus" is written on one of Aileron's water features. Courtesy of Aileron To continue reading this content, please enable JavaScript in your browser ...
Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities Trial is evaluating ALRN-6924 as a treatment to ...
Aileron Therapeutics’ unraveling has entered its endgame. An early look at phase 1b data persuaded the biotech to call it quits on development of its sole drug candidate—and lay off most of its ...
WALTHAM, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address ...
Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. Now, the biotech has distanced itself from its premerger form by rebranding ...
Brett T. Evans has more than a decade of experience driving, writing about, and evaluating automobiles. His early career comprised writing about pre- and post-war classic cars, as well as late-model ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results